abstract n engl j med 378;15 nejm.org April 12,
|
|
- Tabitha Lucas
- 6 years ago
- Views:
Transcription
1 The new england journal of medicine established in 1812 April 12, 2018 vol. 378 no. 15 Zika Virus Shedding in Semen of Symptomatic Infected Men Paul S. Mead, M.D., M.P.H., Nisha K. Duggal, Ph.D., Sarah A. Hook, M.A., Mark Delorey, Ph.D., Marc Fischer, M.D., M.P.H., Dana Olzenak McGuire, Ph.D., Heidi Becksted, M.P.H., Ryan J. Max, M.P.H., Michael Anishchenko, Ph.D., Amy M. Schwartz, M.P.H., Wen Pin Tzeng, Ph.D., Christina A. Nelson, M.D., M.P.H., Erin M. McDonald, Ph.D., John T. Brooks, M.D., M.P.H., Aaron C. Brault, Ph.D., and Alison F. Hinckley, Ph.D. abstract BACKGROUND Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has been linked to adverse birth outcomes. Previous reports have shown that person-to-person transmission can occur by means of sexual contact. METHODS We conducted a prospective study involving men with symptomatic ZIKV infection to determine the frequency and duration of ZIKV shedding in semen and urine and to identify risk factors for prolonged shedding in these fluids. Specimens were obtained twice per month for 6 months after illness onset and were tested by realtime reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay for ZIKV RNA and by Vero cell culture and plaque assay for infectious ZIKV. RESULTS A total of 1327 semen samples from 184 men and 1038 urine samples from 183 men were obtained 14 to 304 days after illness onset. ZIKV RNA was detected in the urine of 7 men (4%) and in the semen of 60 (33%), including in semen samples from 22 of 36 men (61%) who were tested within 30 days after illness onset. ZIKV RNA shedding in semen decreased substantially during the 3 months after illness onset but continued for 281 days in 1 man (1%). Factors that were independently associated with prolonged RNA shedding included older age, less frequent ejaculation, and the presence of certain symptoms at the time of initial illness. Infectious ZIKV was isolated from 3 of 78 semen samples with detectable ZIKV RNA, all obtained within 30 days after illness onset and all with at least 7.0 log 10 ZIKV RNA copies per milliliter of semen. From the Centers for Disease Control and Prevention (CDC) National Center for Emerging and Zoonotic Infectious Diseases, Fort Collins, CO (P.S.M., N.K.D., S.A.H., M.D., M.F., H.B., R.J.M., M.A., A.M.S., W.-P.T., C.A.N., E.M.M., A.C.B., A.F.H.); and the CDC National Center for Chronic Disease Prevention and Health Promotion (D.O.M.) and the CDC National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention (J.T.B.) both in Atlanta. Address reprint requests to Dr. Mead at the Division of Vector- Borne Diseases, Centers for Disease Control and Prevention, 3156 Rampart Rd., Fort Collins, CO 80521, or at pmead@ cdc.gov. Drs. Mead and Duggal contributed equally to this article. N Engl J Med 2018;378: DOI: /NEJMoa Copyright 2018 Massachusetts Medical Society. CONCLUSIONS ZIKV RNA was commonly present in the semen of men with symptomatic ZIKV infection and persisted in some men for more than 6 months. In contrast, shedding of infectious ZIKV appeared to be much less common and was limited to the first few weeks after illness onset. (Funded by the Centers for Disease Control and Prevention.) n engl j med 378;15 nejm.org April 12,
2 The new england journal of medicine Zika virus (ZIKV) is a single-stranded RNA virus that is transmitted by aedes mosquitoes. The illness in humans is generally mild. Nevertheless, infection has been linked to congenital microcephaly and other adverse pregnancy outcomes and to the Guillain Barré syndrome. 1,2 Originally discovered in Uganda, ZIKV has emerged recently in the Pacific region and in the Americas, where it has spread rapidly to more than 48 countries, including the United States. 3,4 Sexual transmission of ZIKV was first posited in 2011 by a researcher whose wife became ill after his return from Senegal to the United States. 5 The virus was subsequently detected in the semen of a Tahitian man in whom hematospermia had developed after an acute febrile illness. 6 With the emergence of ZIKV in the Americas, confirmed or probable cases of sexual transmission have now been reported in at least 13 countries Most documented cases have involved sexual transmission from symptomatic men to women, although transmission from a man to another man, from a woman to a man, and from an asymptomatic man to a woman has been reported The potential implications of sexual transmission of ZIKV are far-reaching Perhaps most importantly, it has been proposed that sexual transmission might pose a risk of fetal infection that is greater than the risk associated with mosquito-borne transmission. 18 If so, the interruption of sexual transmission could play a critical role in preventing the serious complications that have been associated with fetal infection. Public health agencies in several countries have issued interim guidance recommending that condomless sexual contact with men who have been exposed to ZIKV or who have ZIKV infection should be avoided especially by women who are or may become pregnant for periods ranging from 8 weeks to at least 6 months after symptom onset or the last potential ZIKV exposure. 13,21,22 In subsequent reports, ZIKV RNA was found in the semen of infected men more than 180 days after illness onset, arousing concern that the period of avoidance might need to be lengthened. 23,24 To better inform public health recommendations, we conducted a prospective study involving 225 men with confirmed, symptomatic ZIKV infection. Our goals were to determine more precisely the frequency, duration, and pattern of ZIKV shedding in semen and urine and to identify risk factors for prolonged shedding in these body fluids. Methods Enrollment and Specimens Cases of ZIKV infection were identified by state and local health departments on the basis of reports from clinicians and laboratories. Cases were confirmed according to the laboratory criteria listed in the 2016 Council of State and Territorial Epidemiologists interim surveillance case definition. 25 Local health authorities contacted men who had confirmed symptomatic infection, informed them of the study, and referred interested candidates to staff of the Centers for Disease Control and Prevention (CDC) for screening, obtaining of informed consent, and enrollment. Enrollment was limited to men 18 years of age or older who resided in the continental United States or Hawaii. Men were excluded if they were incarcerated or did not speak English or Spanish. Baseline information was obtained, and a collection kit with return postage was mailed to the participant s home. Participants were asked to provide urine and semen samples, obtained in that order. Specimens were shipped overnight with cold packs. Additional kits were sent every 2 weeks thereafter, until 6 months from the date of the participant s onset of illness. Participants whose specimens still tested positive for ZIKV RNA at the end of 5 months were allowed to continue submitting samples until two consecutive samples tested negative. With each specimen submission, participants were asked to complete a seven-question survey regarding current urogenital symptoms and frequency of ejaculations in the 7 days before the sample was obtained. Testing results were provided to the enrolled participants at the end of participation. The study was approved by the CDC institutional review board and by the Office of Management and Budget, and oral informed consent was obtained from all the participants. Laboratory Testing Semen and urine samples were tested at the CDC Division of Vector-Borne Diseases. ZIKV RNA was assayed by real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay with 1378 n engl j med 378;15 nejm.org April 12, 2018
3 Zika Virus Shedding in Semen the use of Asian genotype specific primers, with a lower limit of detection of 4 RNA copies per reaction or 800 RNA copies per milliliter (for details of the assays and validation, see the Supplementary Appendix, available with the full text of this article at NEJM.org). Semen samples with ZIKV RNA that was detectable by RT-PCR were tested at a 1:10 dilution by Vero cell plaque assay for infectious particles. 26 Samples were selected for culturing nonrandomly, with preference given to samples that had been obtained sooner after illness onset and samples with higher viral RNA loads. The 1:10 dilution was necessary to prevent nonspecific cytopathic effects that may occur when undiluted semen samples with undetectable levels of viral RNA are inoculated onto Vero cells. Viral isolation was also attempted by inoculating diluted semen samples onto confluent monolayers of Vero cells in individual wells of six-well plates; viral replication was verified by using RT-PCR to test supernatant at multiple time points after inoculation for increasing levels of viral RNA. 27 Statistical Analysis Risk factors for viral RNA shedding were assessed by fitting a Weibull distribution to the number of days between illness onset and the clearance of ZIKV (see the Supplementary Appendix). Factors that were evaluated for association with duration of RNA shedding were the age of the participant, vasectomy history, average number of ejaculations per week during the study (not counting when the samples were obtained), ongoing pain or burning with urination or blood in the semen, and symptoms at the time of the initial illness, specifically the presence of fever, joint pain, rash, or conjunctivitis. Interaction was assessed for each possible pairing of risk factors. Results Study Population Among the 274 eligible men who were contacted, 225 were enrolled, and 185 participated by submitting at least one semen sample or one urine sample (Fig. S1 in the Supplementary Appendix). There were no significant differences in terms of age or symptoms of illness between enrollees who submitted specimens and those who did not submit specimens. Participants were residents of 24 U.S. states, the median age of the participants Table 1. Characteristics of the 185 Enrolled Participants Who Submitted Samples. Characteristic Value Symptom of initial illness no./total no. (%) Rash 176/183 (96) Fever 138/174 (79) Joint pain 140/183 (77) Conjunctivitis 95/177 (54) Bloody semen 8/177 (5) History of vasectomy no./total no. (%) 29/176 (16) Time from illness onset to first sample no. (%) days 40 (22) days 70 (38) days 28 (15) 91 days 47 (25) was 37 years (range, 18 to 69), and all but 1 participant had become infected during international travel. The laboratory basis for diagnosis was the detection of ZIKV RNA in a body fluid by RT-PCR in 183 of 225 men (81%), with or without serologic testing, and by serologic testing in 40 men (18%). A total of 2 men (1%) received a diagnosis of confirmed ZIKV infection as a result of testing of an unknown type. The majority of participants reported rash, fever, joint pain, and conjunctivitis as features of their initial illness, and 8 of 177 (5%) reported seeing blood in their semen during or shortly after illness onset (Table 1). A total of 2 men (1%) had disease that was linked to sexual transmission, and 29 of 176 men (16%) reported having undergone vasectomy. ZIKV RNA in Semen A total of 1327 semen samples were submitted by 184 participants, with a range of 1 to 19 samples per participant (median, 4 samples); 82% of the samples were received within 1 day after they had been obtained by the participant. The median time from illness onset to collection of the participant s first sample was 42 days (range, 14 to 222) (Table 1); the last sample for any participant was obtained 304 days after illness onset. Overall, participants reported ejaculating an average of 3 times (range, 0 to >10) during the 7 days before the sample was obtained; less than 3% of the participants reported dysuria or other genitourinary symptoms. n engl j med 378;15 nejm.org April 12,
4 The new england journal of medicine Table 2. Zika Virus (ZIKV) RNA Detection in Semen and Urine Samples over Time, According to Sample and Participant. Time since Illness Onset Positive Result in Semen Positive Result in Urine Samples Participants Samples Participants no./total no. (%) days 22/40 (55) 22/36 (61) 5/42 (12) 5/40 (12) days 76/172 (44) 48/112 (43) 3/172 (2) 3/107 (3) days 42/217 (19) 28/131 (21) 0/217 0/ days 13/229 (6) 9/132 (7) 0/225 0/ days 10/229 (4) 8/137 (6) 0/200 0/ days 6/247 (2) 2/141 (1) 0/145 0/91 >180 days* 5/96 (5) 1/91 (1) 0/37 0/36 Total 174/1230 (14) 60/184 (33) 8/1038 7/183 (4) * Data include those collected during extended sampling in men whose samples remained positive for ZIKV RNA on reverse-transcriptase polymerase-chain-reaction assay at 180 days, as well as terminal samples for other participants who submitted samples slightly more than 180 days after illness onset. Log 10 ZIKV RNA Load (copies/ml of semen) Culture Results Positive Negative Not cultured Days since Illness Onset Figure 1. Estimated Viral RNA Load and Culture Results in Semen Samples from 184 Men, Shown is the estimated viral RNA load and culture results for semen samples with Zika virus (ZIKV) RNA detected by reverse-transcriptase polymerasechain-reaction (RT-PCR) assay, according to days since illness onset, among 184 enrolled U.S. residents with symptomatic ZIKV infection in the period. Owing to specimen leakage during shipping or to inadequate volume, 97 samples could not be tested. Among the tested semen samples, 174 of 1230 (14%) were positive for ZIKV RNA according to RT-PCR. The highest viral RNA load detected in semen was 8.4 log 10 RNA copies per milliliter (Fig. 1). Overall, 60 of 184 men (33%) had at least 1 RNA-positive semen sample (range, 1 to 16; median, 3 positive samples per participant). The observed rates of viral RNA detection were similar in the subgroup of men who reported having undergone vasectomy, with ZIKV RNA detected in 34 of 201 samples (17%) that had been obtained from 7 of 28 men (25%) who had undergone vasectomy. The median viral RNA loads for the first positive sample were significantly lower in men who had undergone vasectomy than in men who had not, with a median of 3.6 log 10 RNA copies per milliliter versus 5.6 log 10 RNA copies per milliliter (χ 2 = 7.6, P = 06). Among men who submitted samples within 30 days after illness onset, 61% had detectable ZIKV RNA in their semen. This proportion decreased to 7% or less among men who submitted samples more than 90 days after illness onset (Table 2). The number of ZIKV RNA copies generally decreased in subsequent samples from the same man. However, the rate of decrease 1380 n engl j med 378;15 nejm.org April 12, 2018
5 Zika Virus Shedding in Semen varied greatly. Intermittent shedding, defined as a ZIKV RNA negative sample followed by a positive sample, was observed in 8 of 60 men (13%) (Fig. S2 in the Supplementary Appendix). On a per-sample basis, the frequency of a ZIKV RNA positive sample following a negative one was 1% (8 of 868 samples). Four men were enrolled for extended participation beyond the planned 6-month period. The longest duration of ZIKV RNA detection in semen was 281 days after illness onset in a man who had undergone vasectomy (Participant P28) (Fig. S2 in the Supplementary Appendix). Three of the four men reported that they did not have a known immunocompromising condition; information on immune status was not available for the fourth man. ZIKV RNA in Urine A total of 8 of 1038 urine samples (1%) submitted by 183 men yielded evidence of ZIKV RNA according to RT-PCR. The numbers of ZIKV RNA copies per milliliter of urine were lower than in semen, with a maximum level detected of 4.6 log 10 RNA copies per milliliter of urine and a median level of 2.9 log 10 RNA copies per milliliter. The 8 urine samples with ZIKV RNA detected were obtained from 7 men who had ZIKV RNA detected in contemporaneous semen samples; all 8 samples were obtained within 40 days after illness onset. Risk Factors for ZIKV RNA in Semen and Predicted Maximum Duration of Persistence Under the assumption of a Weibull distribution with averaging over all the covariate effects in the model, the mean time to the clearance of ZIKV RNA from semen was 54 days (95% confidence interval, 53 to 55). On the basis of our results, we estimated that only 5% of men would have detectable levels of ZIKV RNA at 158 days after the onset of symptoms (upper boundary of the 95% confidence interval, 186 days) and only 1% of men would have detectable levels of ZIKV RNA at 240 days after illness onset (upper boundary of the 95% confidence interval, 299 days) (Fig. 2). Factors that were independently associated with a longer time to RNA clearance from semen were increasing age (P = 1), symptoms at the time of initial illness (presence of conjunctivitis, P = 2; absence of joint pain, P = 03), and less frequent ejaculation (P = 02) (Fig. 3). On average, ZIKV RNA was detected 12 days longer in men who were 50 years of age than in those who were 30 years of age and 12 days longer in men who reported having had conjunctivitis during their initial illness than in those who did not. Men who reported no joint pain during their initial illness had ZIKV RNA detected 27 days longer than did men who reported joint pain. The largest overall effect, however, was that of ejaculatory frequency (Fig. 3B). After controlling for age, we found that men who ejaculated four times per week during the study cleared ZIKV RNA 21 days earlier than did men who ejaculated once per week. Among the 60 men who had at least one positive semen sample, the median ejaculatory frequency during shedding was nearly identical to that after shedding (see the Supplementary Appendix) Figure 2. Estimated Proportion of Semen Samples Positive for ZIKV on RT-PCR, According to Days since Illness Onset. Shown is the estimated proportion of semen samples that were positive for ZIKV on RT-PCR, according to the number of days since illness onset, evaluated as the average of all the covariate effects in the model. The solid black curve is the decline in the proportion of positive samples as estimated by the model. The dotted curve is the upper boundary of the 95% confidence interval of the decline. The horizontal dashed line at 1 indicates the estimated point at which the proportion of positive samples reached 1%. We estimate that only 1% of the participants would have had positive samples at 240 days. The upper boundary of the 95% confidence interval of this estimate is 299 days. n engl j med 378;15 nejm.org April 12,
6 The new england journal of medicine A ZIKV Clearance According to Age 20 yr of age 30 yr of age 40 yr of age 50 yr of age 60 yr of age B ZIKV Clearance According to Number of Ejaculations per Week 0 per wk 2 per wk 4 per wk 6 per wk 8 per wk 10 per wk 12 per wk C ZIKV Clearance According to Presence or Absence of Conjunctivitis D ZIKV Clearance According to Presence or Absence of Joint Pain Conjunctivitis No joint pain No conjunctivitis Joint pain Figure 3. Estimated Proportion of Semen Samples Positive for ZIKV on RT-PCR, According to Days since Illness Onset, for Independently Associated Covariates. Shown is the estimated proportion of semen samples that were positive for ZIKV on RT-PCR, at different time points after illness onset, according to each of four independently associated covariates: age of the participant (P = 1) (Panel A), mean frequency of ejaculation per week (P = 02) (Panel B), conjunctivitis during initial illness (P = 2) (Panel C), and absence of joint pain during initial illness (P = 03) (Panel D). The estimates were based on the testing of 1230 semen samples that had been obtained from 184 U.S. residents with symptomatic ZIKV infection. Isolation of ZIKV from Semen Among the semen samples in which ZIKV RNA was detected by RT-PCR, 78 samples that had been obtained from 46 men were tested by culture. Infectious ZIKV was detected by a plaque assay in 3 of 19 samples that were obtained within 30 days after illness onset but in none of 59 samples that were obtained later. The 3 samples that yielded infectious virus were obtained from 3 participants and were the only samples with at least 7.0 log 10 ZIKV RNA copies per milliliter of semen (Fig. 1). The presence of infectious ZIKV in the sample with 8.4 log 10 ZIKV RNA copies per milliliter was also shown by inoculation of the initial semen sample on Vero cells, followed by quantification of viral RNA in supernatant by RT-PCR at multiple times after inoculation. The ZIKV RNA copy number in these 3 samples was observed to increase over time. Infectious ZIKV was not detected in the next available sample from two of these participants; these samples were obtained 38 days and 59 days after illness onset and had ZIKV RNA copy numbers of 5.8 and 3.1 log 10 RNA copies per milliliter, respectively. The next available sample from the third participant was obtained 76 days after illness onset and had no detectable ZIKV RNA n engl j med 378;15 nejm.org April 12, 2018
7 Zika Virus Shedding in Semen ZIKV RNA was initially detected by RT-PCR in the cell-culture supernatant of 30 additional samples that had been inoculated onto Vero cells. However, copy numbers were lower than in the original sample and decreased over time, findings that suggest carryover of viral RNA from the original sample rather than the presence of infectious virus. Efforts to culture infectious ZIKV from the 8 urine samples with detectable ZIKV RNA were unsuccessful. Discussion In this study, more than 60% of men with symptomatic ZIKV infection were observed to have ZIKV RNA in their semen during the first 30 days after illness onset. The maximum viral load was 8.4 log 10 RNA copies per milliliter. ZIKV RNA shedding in semen decreased rapidly during the 3 months after the onset of illness. However, persistence for up to 9 months occurred in a small percentage of men. These observations are consistent with those in previous case reports and with interim results from smaller studies. 6,8,28,29 The results of multivariable analysis suggest that men who were older or who ejaculated infrequently were more likely to have prolonged shedding in semen than those who were younger or had more frequent ejaculation. The detection of ZIKV RNA in urine was rare in this study, probably because of the timing of the initial specimen collection. Previous studies have shown that shedding of ZIKV in urine, although initially common, declines rapidly during the first few weeks after illness onset. 29,30 In contrast to the frequent and prolonged shedding of ZIKV RNA in semen, the shedding of infectious ZIKV that could be cultured was rare, short-lived, and limited to the few samples with at least 7.0 log 10 ZIKV RNA copies per milliliter of semen. None of the 75 cultured samples with RNA loads lower than 7.0 log 10 per milliliter yielded infectious ZIKV, and no sample that was obtained more than 30 days after illness onset yielded infectious ZIKV. Similar findings have been reported in murine models. 31 Attempts by others to culture ZIKV from human semen at later time points have generally been unsuccessful. 9,32,33 In one case report, ZIKV RNA was detected in Vero cell cultures inoculated with semen that had been obtained 69 days after illness onset; it was unstated, however, whether the RNA copy number increased during culture. 34 In our study, culture supernatants often had detectable but declining ZIKV RNA copy numbers, which suggests passive carryover of RNA from the original inoculation rather than viral replication. The divergent results generated by culture and RT-PCR can be adjudicated by comparing them with epidemiologic data about known instances of sexual transmission. Among documented cases of male-to-partner sexual transmission, all have occurred within 41 days after illness onset in the source male partner, and most have occurred within 20 days. 7-9,12,13,35 The absence of reported events occurring at later time points suggests that transmission events coincide with the period during which the virus can be cultured and that detection of ZIKV RNA by RT-PCR may overstate the duration and magnitude of the risk of sexual transmission. Several factors appear to independently influence the rate at which ZIKV RNA is cleared from the semen of infected men. Prolonged shedding in older men may be related to either structural changes in the reproductive tract (e.g., prostatic hypertrophy) or perhaps reduced immunity. The observed associations with conjunctivitis and arthralgia may be markers of infectious or immunologic events also occurring in the testis or genitourinary mucosa, which in turn might affect the duration of shedding. Regarding the association between the duration of RNA shedding and ejaculatory frequency, one possible explanation is that men feel ill while shedding ZIKV and are therefore less likely to engage in sexual activity. If so, one would expect men s ejaculatory frequency to increase after shedding stopped. However, among men who had at least one positive semen sample, the mean ejaculatory frequency was the same during and after shedding. An alternative explanation is that participant-specific differences in ejaculatory frequency influence the rate at which viral material is flushed from the genital tract. The intermittent detection of ZIKV RNA in semen was noted in a few participants. This finding is consistent with previous reports 24,29 and suggests that a single negative result cannot rule out future shedding of ZIKV RNA. Nevertheless, the likelihood of detecting ZIKV RNA in semen when it was not detected in a previous sample appears to be less than 1%. Our findings are subject to several limitations. n engl j med 378;15 nejm.org April 12,
8 The new england journal of medicine They do not necessarily pertain to men with asymptomatic infection, although a recent study showed similar rates of ZIKV RNA shedding in semen of asymptomatic blood donors with viremia. 20 The clinical significance of low levels of ZIKV RNA in semen remains uncertain, and without access to medical records, it was not possible to evaluate the potential effect of underlying medical conditions on the duration of shedding. Some specimens could not be tested because of leakage, and the collection of samples at home and the delay associated with specimen transport and storage may have compromised the quality of other samples. Important questions regarding sexual transmission of ZIKV remain. Factors underlying the ZIKV tropism for human reproductive tissues have yet to be identified, 28,36 and although fetal infection has been reported after sexual or intravaginal ZIKV exposure in animal models 31,37 and possibly in humans, 38 it is unknown whether maternal infection through sex poses the same risks to the fetus as infection through mosquito bite. A better understanding of these issues is needed to guide the development of effective prevention strategies. The views expressed in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). Supported by the CDC. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the study participants and our colleagues in state and local health departments and at the CDC, especially Alexander Davidson, Sally Slavinski, Marcy Layton, Charsey Cole Porse, Jacklyn Wong, Jennifer White, Mary Jo Polfleit, Katie Kurkjian, Hanna Oltean, Pat Ryan, Katherine Feldman, Connie Austin, Rebecca Osborn, Julia Jensen, Jennifer House, Taryn Stevens, Julie Shaffner, Rendi Murphree, Carina Blackmore, Sarah Y. Park, Amanda Feldpausch, Sara Robinson, Katie Brown, Randy Nelson, Abigail Mathewson, Carolyn Fredette, Miguella Mark- Carew, Carl Williams, Rachel Radcliffe, Alain Pujolar, Pauline Lucas, Natalie Kwit, Brad Biggerstaff, and Stacey Bartlett. References 1. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects reviewing the evidence for causality. N Engl J Med 2016; 374: Dos Santos T, Rodriguez A, Almiron M, et al. Zika virus and the Guillain Barré syndrome case series from seven countries. N Engl J Med 2016; 375: Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med 2016; 374: Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. Lancet 2017; 390: Foy BD, Kobylinski KC, Chilson Foy JL, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis 2011; 17: Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. Emerg Infect Dis 2015; 21: Hills SL, Russell K, Hennessey M, et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission continental United States, MMWR Morb Mortal Wkly Rep 2016; 65: D Ortenzio E, Matheron S, Yazdanpanah Y, et al. Evidence of sexual transmission of Zika virus. N Engl J Med 2016; 374: Frank C, Cadar D, Schlaphof A, et al. Sexual transmission of Zika virus in Germany, April Euro Surveill 2016; 21: Fréour T, Mirallié S, Hubert B, et al. Sexual transmission of Zika virus in an entirely asymptomatic couple returning from a Zika epidemic area, France, April Euro Surveill 2016; 21: Turmel JM, Abgueguen P, Hubert B, et al. Late sexual transmission of Zika virus related to persistence in the semen. Lancet 2016; 387: Venturi G, Zammarchi L, Fortuna C, et al. An autochthonous case of Zika due to possible sexual transmission, Florence, Italy, Euro Surveill 2016; 21: Prevention of sexual transmission of Zika virus. Interim guidance update. Geneva: World Health Organization, September 2016 ( iris/ handle/ 10665/ ). 14. World Health Organization. Situation report. March 10, 2017 ( emergencies/ zika-virus/ situation-report/ en/). 15. Deckard DT, Chung WM, Brooks JT, et al. Male-to-male sexual transmission of Zika virus Texas, January MMWR Morb Mortal Wkly Rep 2016; 65: Davidson A, Slavinski S, Komoto K, Rakeman J, Weiss D. Suspected femaleto-male sexual transmission of Zika virus New York City, MMWR Morb Mortal Wkly Rep 2016; 65: Brooks RB, Carlos MP, Myers RA, et al. Likely sexual transmission of Zika virus from a man with no symptoms of infection Maryland, MMWR Morb Mortal Wkly Rep 2016; 65: Rowland A, Washington CI, Sheffield JS, Pardo-Villamizar CA, Segars JH. Zika virus infection in semen: a call to action and research. J Assist Reprod Genet 2016; 33: Moreira J, Peixoto TM, Siqueira AM, Lamas CC. Sexually acquired Zika virus: a systematic review. Clin Microbiol Infect 2017; 23: Musso D, Richard V, Teissier A, et al. Detection of Zika virus RNA in semen of asymptomatic blood donors. Clin Microbiol Infect 2017; 23(12): 1001.e e Brooks JT, Friedman A, Kachur RE, LaFlam M, Peters PJ, Jamieson DJ. Update: interim guidance for prevention of sexual transmission of Zika virus United States, July MMWR Morb Mortal Wkly Rep 2016; 65: Oster AM, Russell K, Stryker JE, et al. Update: interim guidance for prevention of sexual transmission of Zika virus United States, MMWR Morb Mortal Wkly Rep 2016; 65: Nicastri E, Castilletti C, Liuzzi G, Iannetta M, Capobianchi MR, Ippolito G. Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February Euro Surveill 2016; 21: Barzon L, Pacenti M, Franchin E, et al. Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January Euro Surveill 2016; 21: Zika virus disease, non-congenital infection and Zika virus, nongenital infection 2016 interim case definition, approved February 26, Atlanta: Council of State and Territorial Epidemiologists, 2016 ( / wwwn.cdc.gov/ nndss/ conditions/ zika/ case-definition/ 2016/ 02/ 26/ ) n engl j med 378;15 nejm.org April 12, 2018
9 Zika Virus Shedding in Semen 26. Weger-Lucarelli J, Duggal NK, Bullard- Feibelman K, et al. Erratum for Weger- Lucarelli et al., Development and Characterization of Recombinant Virus Generated from a New World Zika Virus Infectious Clone. J Virol 2017; 91(8): e Jang HC, Park WB, Kim UJ, et al. First imported case of Zika virus infection into Korea. J Korean Med Sci 2016; 31: Mansuy JM, Dutertre M, Mengelle C, et al. Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? Lancet Infect Dis 2016; 16: Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika virus in body fluids preliminary report. N Engl J Med. DOI: /NEJMoa Bingham AM, Cone M, Mock V, et al. Comparison of test results for Zika virus RNA in urine, serum, and saliva specimens from persons with travel-associated Zika virus disease Florida, MMWR Morb Mortal Wkly Rep 2016; 65: Duggal NK, Ritter JM, Pestorius SE, et al. Frequent Zika virus sexual transmission and prolonged viral RNA shedding in an immunodeficient mouse model. Cell Rep 2017; 18: Froeschl G, Huber K, von Sonnenburg F, et al. Long-term kinetics of Zika virus RNA and antibodies in body fluids of a vasectomized traveller returning from Martinique: a case report. BMC Infect Dis 2017; 17: Matheron S, d Ortenzio E, Leparc- Goffart I, Hubert B, de Lamballerie X, Yazdanpanah Y. Long-lasting persistence of Zika virus in semen. Clin Infect Dis 2016; 63: Arsuaga M, Bujalance SG, Díaz-Menéndez M, Vázquez A, Arribas JR. Probable sexual transmission of Zika virus from a vasectomised man. Lancet Infect Dis 2016; 16: Harrower J, Kiedrzynski T, Baker S, et al. Sexual transmission of Zika virus and persistence in semen, New Zealand, Emerg Infect Dis 2016; 22: Govero J, Esakky P, Scheaffer SM, et al. Zika virus infection damages the testes in mice. Nature 2016; 540: Yockey LJ, Varela L, Rakib T, et al. Vaginal exposure to Zika virus during pregnancy leads to fetal brain infection. Cell 2016; 166(5): e Oliveira DB, Almeida FJ, Durigon EL, et al. Prolonged shedding of Zika virus associated with congenital infection. N Engl J Med 2016; 375: Copyright 2018 Massachusetts Medical Society. n engl j med 378;15 nejm.org April 12,
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mead PS, Duggal NK, Hook SA, et al. Zika virus shedding in
More informationZika: Deet, There It Is. Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS
Zika: Deet, There It Is Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS Disclosure I have no financial disclosures or conflicts of interest Lessons from Rubella At peak of rubella epidemic
More informationPersistence of Zika Virus in Body Fluids Preliminary Report
Original Article Persistence of Zika Virus in Body Fluids Preliminary Report Gabriela Paz Bailey, M.D., Ph.D., Eli S. Rosenberg, Ph.D., Kate Doyle, M.P.H., Jorge Munoz Jordan, Ph.D., Gilberto A. Santiago,
More informationClinical Policy: Diagnostic Testing for Zika Virus Reference Number: CP.MP.111 Effective Date: 06/16
Clinical Policy: Diagnostic Testing for Zika Virus Reference Number: CP.MP.111 Effective Date: 06/16 Last Review Date: 05/16 Revision Log See Important Reminder at the end of this policy for important
More informationGuidance for Investigation and Management of Zika Virus Infection
Guidance for Investigation and Management of Zika Virus Infection Update: February 11, 2016 Public Health Agency of Canada has issued recommendations from the Committee to Advise on Tropical Medicine and
More information*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a
*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a GDPH epidemiologist 404-657-2588, 8-5 pm M-F for current
More informationWhat is Zika virus? What are the symptoms and complications of Zika virus infection? Are cases expected in Canada?
What is Zika virus? Zika Virus Update for Healthcare Professionals Updated June 22, 2016; italicized text indicates clarification of wording contained in previous versions. Zika virus is a Flavivirus transmitted
More informationZIKA VIRUS OUTBREAK. JANET B. EDDY M.D. KU-WICHITA PGY2 OBSTETRICS AND GYNECOLOGY RESIDENCY Dominican Republic 2016
ZIKA VIRUS OUTBREAK JANET B. EDDY M.D. KU-WICHITA PGY2 OBSTETRICS AND GYNECOLOGY RESIDENCY Dominican Republic 2016 Zika time line 1947: 1 st isolated in rhesus monkey in Zika forest of Uganda 1 12/2013:
More informationFact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay. September 7, 2016
Dear Health Care Provider: Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay September 7, 2016 The U.S. Food and Drug Administration (FDA) has issued an Emergency
More informationDetection and identification of travel-acquired Zika virus infections
Detection and identification of travel-acquired Zika virus infections Sarah K. White, MPH Department of Environmental and Global Health College of Public Health and Health Professions November 4, 2016
More information: AccuPower ZIKV(DENV, CHIKV) Multiplex Real-Time RT-PCR Kit. Copyright, Bioneer Corporation. All rights reserved.
: AccuPower ZIKV(DENV, CHIKV) Multiplex Real-Time RT-PCR Kit Copyright, Bioneer Corporation. All rights reserved. 1. Offers superior diagnostic accuracy compared to immunoassay Allows precision diagnosis,
More informationZIKA VIRUS TESTING GUIDANCE, UPDATED 7/20/2016
Section 1: Which patients should be offered testing? SUMMARY OF CATEGORIES OF PATIENTS WHO SHOULD BE TESTED FOR ZIKA 1) Pregnant women who traveled to a Zika-affected area (see link to current list in
More informationUpdates in Infectious Diseases. Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016
Updates in Infectious Diseases Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016 Disclosures No financial relationships or affiliations to disclose Overview Activity Pre-Test
More informationWhat s Lurking out there??????
What s Lurking out there?????? Dave Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene david.warshauer@slh.wisc.edu WISCONSIN STATE LABORATORY OF HYGIENE
More informationThis memo is intended to provide information to NC clinicians and laboratories regarding diagnosis, management and reporting of Zika virus infection.
May 18, 2016 (replaces version dated March 31, 2016) To: From: North Carolina Health Care Providers and Laboratories Megan Davies, MD, State Epidemiologist Scott Zimmerman, DrPH, MPH, HCLD (ABB), State
More informationZika Virus Update. Partner Webinar 05/12/2016
Zika Virus Update Partner Webinar 05/12/2016 Today s presenters Patricia Quinlisk, MD, MPH, Medical Director /State Epidemiologist Ann Garvey, DVM, MPH, MA, State Public Health Veterinarian/ Deputy State
More informationZika Virus Update for Emergency Care Providers
Zika Virus Update for Emergency Care Providers What is this Zika Virus? Jeff Doerr Epidemiologist Southeastern Idaho Public Health Zika Virus Single stranded RNA virus Genus Flavivirus, Family Flaviviridae
More informationZIKA UPDATE NOVEMBER Ministry of Health, Barbados
ZIKA UPDATE NOVEMBER 2016 Ministry of Health, Barbados Zika Virus Disease Objectives By the end of this presentation you should be able: To recount the track of the current global Zika virus epidemic To
More informationZIKA VIRUS. John J. Russell MD May 27, 2016
John J. Russell MD May 27, 2016 HISTORY Discovered 1947 Zika Forest of Uganda in rhesus monkeys, thus the name Found in humans in Africa in 1952 Not considered a public health threat until outbreak in
More informationA RELOOK AT ZIKA VIRAL INFECTION AND ITS LATEST OUTBREAK IN INDIA
24 th December 2018 A RELOOK AT ZIKA VIRAL INFECTION AND ITS LATEST OUTBREAK IN INDIA BACKGROUND Zika virus infection, which erupted on a large scale in 2015-2016, has infected more than 1.5 million people.
More informationZika Virus: The Olympics and Beyond
Zika Virus: The Olympics and Beyond Alice Pong, MD Pediatric Infectious Diseases Rady Children s Hospital-San Diego University of California, San Diego Disclosures I have no disclosures to report 1 Objectives
More informationPublic Health Image Library. CDC/ Cynthia Goldsmith. Image #
Zika Virus Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar,
More informationZIKA Jordan H. Perlow MD Banner University Medical Center Division of Maternal Fetal Medicine Phoenix Perinatal Asoociates
ZIKA Jordan H. Perlow MD Banner University Medical Center Division of Maternal Fetal Medicine Phoenix Perinatal Asoociates Disclosures I have no relevant financial relationships to disclose or conflicts
More informationZika Virus Dr Conor Doherty
Zika Virus Dr Conor Doherty Zika Virus Single stranded RNA enveloped icosahedral virus Flavivirus (e.g. dengue, yellow feve er) First described in Zika forest in Uganda in 1947 Initial enzootic monkey
More informationZika Virus. Centers for Disease Control and Prevention
Centers for Disease Control and Prevention Zika Virus Ingrid Rabe Medical Epidemiologist Arboviral Diseases Branch Centers for Disease Control and Prevention February 1, 2016 Zika Virus Single stranded
More informationZika virus infection Interim clinical guidance for Primary Care
Zika virus infection Interim clinical guidance for Primary Care Zika virus infection is a notifiable disease in Ireland under the Infectious Diseases (Amendment) Regulations 2016 (S.I.. 276 of 2016). All
More informationEuropean Centre for Disease Prevention and Control. Zika virus disease
European Centre for Disease Prevention and Control Zika virus disease Stockholm, 19 February 2016 Background information Zika virus is a member of the Flaviviridae family and transmitted by mosquitoes
More informationZika. Nicole Evert, MS Zoonosis Control Branch Department of State Health Services Austin, Texas
Zika Nicole Evert, MS Zoonosis Control Branch Department of State Health Services Austin, Texas Family Flaviviridae, genus Flavivirus Vectors: Aedes aegypti and Aedes albopictus Maintained in a human-mosquito-human
More informationCenters for Disease Control and Prevention Zika Virus in Pregnancy What Midwives Need To Know
Centers for Disease Control and Prevention Zika Virus in Pregnancy What Midwives Need To Know Margaret A. Lampe, RN, MPH Pregnancy and Birth Defects Surveillance Team Zika Virus Emergency Response U.S.
More informationZika Virus and Control Efforts in Arizona
Zika Virus and Control Efforts in Arizona Irene Ruberto, MPH, PhD Epidemiologist Office of Infectious Disease Services Arizona Department of Health Services November 10, 2016 Goal by Humbletree (cc by-nc
More informationZika Preparedness: Lessons for the U.S. Public Health System
Zika Preparedness: Lessons for the U.S. Public Health System Jeffrey Duchin, MD Health Officer, Public Health - Seattle & King County Professor in Medicine, Division of Infectious Diseases Adjunct Professor,
More informationZika Virus Response Planning: Interim Guidance for District and School Administrators in the Continental United States and Hawaii
Zika Virus Response Planning: Interim Guidance for District and School Administrators in the Continental United States and Hawaii Summary What is already known about this topic? Zika virus is transmitted
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: de Laval F, Matheus S, Labrousse T, Enfissi A, Rousset D, Briolant
More informationCDC Responds to ZIKA Zika 101
CDC Responds to ZIKA Zika 101 Updated April 29, 2016 What is Zika virus disease (Zika)? Disease spread primarily through the bite of an Aedes species mosquito infected with Zika virus. Many people infected
More informationCarol M. Smith, M.D., M.P.H. Commissioner of Health and Mental Health Ulster County Department of Health and Mental Health May 20, 2016
Carol M. Smith, M.D., M.P.H. Commissioner of Health and Mental Health Ulster County Department of Health and Mental Health May 20, 2016 Michael Hein County Executive Zika virus was first discovered in
More informationAs suggested by one fellow student, please consider the CDC's "Final Rules for Control of Communicable Diseases: Interstate and Foreign
As suggested by one fellow student, please consider the CDC's "Final Rules for Control of Communicable Diseases: Interstate and Foreign http://www.cdc.gov/quarantine/ aboutlawsregulationsquarantineisolatio
More informationSexual & Reproductive Health in the Context of Zika Virus
Contents 1 The Zika Epidemic & its Impact on Health 2 Transmission, Pregnancy & Human Rights 3 GTR s Program & Public Policy Recommendations 4 GTR's Recommendations for Health Care Providers 5 GTR's Sexual
More informationZika Virus Guidance for Medical Providers. Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department
Zika Virus Guidance for Medical Providers Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department Kern Perinatal Symposium March 3, 2017 CME DISCLOSURE The Planners,
More informationZika Virus Information and recommendations of the Swiss Expert Committee for Travel Medicine (ECTM)* (Update December 2018) *members listed below
Zika Virus Information and recommendations of the Swiss Expert Committee for Travel Medicine (ECTM)* (Update December 2018) *members listed below Background: In 2015 an explosive spread of the Zika Virus
More informationFigure 1: Suspected and confirmed Zika virus cases reported by countries and territories in the Americas, by epidemiological week (EW)
Zika - Epidemiological Update 17 March 2016 Zika virus Incidence and trends Available data reported suggests a downward trend in reporting of Zika virus cases in the Region of the Americas (Figure 1).
More informationZika Pregnancy and Birth Defects Surveillance
Zika Pregnancy and Birth Defects Surveillance Sowmya Adibhatla, MPH Zika Surveillance and Response Coordinator Overview History/Background Zika cases update Zika virus infection Testing guidance Recommendations
More informationZika Update. PSSNY 2016 Annual Convention June 25, Suzanna Gim, PharmD, MPH
Zika Update PSSNY 2016 Annual Convention June 25, 2016 Suzanna Gim, PharmD, MPH Email: suzannagim@gmail.com Learning Objectives Describe the epidemiology and prevalence of Zika virus disease Identify the
More informationKeeping Microbes at our Doorstep
Keeping Microbes at our Doorstep Mark Loeb MD McMaster University AMMI CANADA-CACMID Plenary on Global Health, Vancouver March 31, 2016 Infection Control Objectives The challenge of anticipating risk Proving
More informationZika Virus. Report to the Standing Committee on Health. Dr. Graham Sher Chief Executive Officer, Canadian Blood Services
Dr. Graham Sher Chief Executive Officer, Services Dr. Dana Devine Chief Medical and Scientific Officer, Services Services Services is an arm s-length organization within the larger health-care system of
More informationZika Virus. Robert Wittler, MD
Zika Virus Robert Wittler, MD Disclosure I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME
More informationZika Virus. Disclosure. Zika Virus 8/26/2016
Zika Virus Robert Wittler, MD Disclosure I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME
More informationIt Takes a Village: Genomic Epidemiology of the Zika Epidemic Developing the Partnerships, Exploring the Data and Sharing the Results
It Takes a Village: Genomic Epidemiology of the Zika Epidemic Developing the Partnerships, Exploring the Data and Sharing the Results Leah D. Gillis, M.S., Ph.D. HCLD (ABB) Laboratory Director Miami Bureau
More informationZika Virus Identifying an Emerging Threat. Florida Department of Health in Miami-Dade County Epidemiology, Disease Control, & Immunization Services
Zika Virus Identifying an Emerging Threat Florida Department of Health in Miami-Dade County Epidemiology, Disease Control, & Immunization Services What is Zika Virus? Zika virus is a vector-borne disease
More informationZika 101 for Occupational Safety and Health Professionals
CDC Responds to ZIKA Zika 101 for Occupational Safety and Health Professionals CDR Jill M. Shugart, MSPH, REHS CDC/National Institute for Occupational Safety and Health Emergency Preparedness and Response
More informationZika virus: Interim guidance information for LMCs (midwives), GPs and other health professionals dealing with Zika virus in pregnancy 5 February 2016
Zika virus: Interim guidance information for LMCs (midwives), GPs and other health professionals dealing with Zika virus in pregnancy 5 February 2016 This interim guidance is the result of consultation
More informationInterim Guidelines for Pregnant Women During a Zika Virus Outbreak United States, 2016
1 of 7 01/02/2016 20:32 Interim Guidelines for Pregnant Women During a Zika Virus Outbreak United States, 2016 Weekly / January 22, 2016 / 65(2);30 33 On January 19, 2016, this report was posted as an
More informationGeographic distribution ZIKV
Shelley M. Wood, RN, BSN, CEN March 16, 2016 Geographic distribution ZIKV 1947 2007 http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2819875/ 1 Current Active Zika transmission WHO declared global health threat
More informationZika Virus. Maternal & Fetal Effects. John P. Elliott, MD Medical Director, Valley Perinatal Services Phoenix, Arizona
Zika Virus Maternal & Fetal Effects John P. Elliott, MD Medical Director, Valley Perinatal Services Phoenix, Arizona Objective of Presentation Sneeka Peeka at Zika Disclosure I have nothing to disclose
More informationFIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS. Preventing Transmission
FIRST CONFIRMED CASE OF IMPORTED ZIKA VIRUS IN HOUSTON, TEXAS Preventing Transmission Objectives Discuss the epidemiology of Zika virus Describe the Zika case investigation of the first confirmed case
More informationZika Virus A Public Health Emergency of Olympic Proportions
Zika Virus A Public Health Emergency of Olympic Proportions Carrie L. Byington M.D.** HA and Edna Benning Presidential Professor Division of Pediatric Infectious Diseases ** With Thanks to Andrew Pavia,
More information16-ID ID-01 Revised 7/29/16 1
16-ID-01 Committee: Infectious Disease Title: Zika Virus Disease and Zika Virus Infection Without Disease, Including Congenital Infections Case Definitions and Addition to the Nationally Notifiable Diseases
More information3/24/2017. CDC S Response to Zika ZIKA 101. Updated February 2, 2017 INTRODUCTION
CDC S Response to Zika ZIKA 101 Updated February 2, 2017 INTRODUCTION 1 What is Zika? Zika virus is spread to people primarily through the bite of an infected Aedes species mosquito (Ae. aegypti and Ae.
More informationWhen infections go viral Zika Virus
When infections go viral Zika Virus John Fangman, MD Associate Professor of Medicine (Infectious Diseases) Senior Medical Director of Ambulatory, Medical College Physicians Medical College of Wisconsin
More informationZika Virus Outbreak in the Americas. J. David Beckham MD Associate Professor of Medicine Division of Infectious diseases University of Colorado SOM
Zika Virus Outbreak in the Americas J. David Beckham MD Associate Professor of Medicine Division of Infectious diseases University of Colorado SOM Learning Objectives Understand the pathogenesis of West
More informationPresentation Overview
Presentation Overview Characteristics of Zika virus Characteristics of Zika virus infection Epidemiology and outbreaks Vector and transmission Clinical symptoms Diagnosis and testing Treatment and prevention
More informationAn Introduction to Dengue, Zika and Chikungunya Viruses
An Introduction to Dengue, Zika and Chikungunya Viruses Natalie Marzec, MD, MPH Zoonoses Epidemiologist 2017 Global Health and Disasters Course Objectives Arbovirus Overview Public Health Activities Clinical
More informationZika Virus in the Primary Care Setting
Zika Virus in the Primary Care Setting Monica McArthur, MD PhD Assistant Professor of Pediatrics Center for Vaccine Development University of Maryland School of Medicine Maryland Chapter ACP Meeting 17
More informationEverything you ever wanted to know about Zika Virus Disease
Everything you ever wanted to know about Zika Virus Disease (in 14 slides) Jon Temte, MD/PhD University of Wisconsin School of Medicine and Public Health 28 January 2016 Zika Virus mosquito-borne flavivirus
More informationZika virus: a new global threat for Dr Gina McAllister Clinical Scientist, Virology
Zika virus: a new global threat for 2016 Dr Gina McAllister Clinical Scientist, Virology Moritz U. G. Kraemer and others The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus
More informationTribal Vector Borne Disease Meeting Inter Tribal Council of Arizona, Inc. Tribal Epidemiology Center February 13-15, 2018 Chandler, AZ
CDC S Response to Zika Tribal Vector Borne Disease Meeting Inter Tribal Council of Arizona, Inc. Tribal Epidemiology Center February 13-15, 2018 Chandler, AZ Dr. Maleeka Glover Lead, Medical Investigations
More informationFight the Bite Zika Virus Webinar District of Columbia Department of Health
Fight the Bite Zika Virus Webinar District of Columbia Department of Health August 2016 Zika Virus Background and Tracking in Washington, DC, and Surrounding States Andrew Hennenfent, DVM, MPH DC Department
More informationFY 2017 President s Budget Request Overview for the National Center on Birth Defects and Developmental Disabilities
National Center on Birth Defects and Developmental Disabilities FY 2017 President s Budget Request Overview for the National Center on Birth Defects and Developmental Disabilities Sascha Chaney Associate
More informationConsiderations for Risk Associated with Zika Virus (ZIKV) Background Document
The following information will be used for a one-hour meeting on February 15, 20 of AATB s Tissue Transmitted Diseases Advisory Group (TTDAG), a subgroup of the Physicians Council. Questions: 1. Should
More informationZika Virus Basics. Flaviviridae Flavivirus Disease Vector Vaccine *Dengue (serotypes 1-4) Zika Virus Basics. Zika Virus Transmission Cycle
Zika: Infection,, and Protection Roxanne P. Liles, Ph.D., MLS(ASCP) CM Assistant Professor of Biology Louisiana State University at Alexandria 318-473-6518 rliles@lsua.edu Zika Virus Basics Virion: Enveloped
More informationTHE ZIKA VIRUS. August 3, Sonia G. Pandit, MPH MBA Chief Executive Officer The Pandit Group
THE ZIKA VIRUS August 3, 2016 Sonia G. Pandit, MPH MBA Chief Executive Officer The Pandit Group sonia@thepanditgroup.com 443-990-1372 www.thepanditgroup.com What Makes Zika Unique? Viral disease (Flavi
More informationRole of a ZIKV CHIM in vaccine evaluation. Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017
Role of a ZIKV CHIM in vaccine evaluation Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017 1 ZIKV congenital syndrome There is increasing evidence from
More informationZIKA VIRUS. Facts & Figures
ZIKA VIRUS Facts & Figures ISSUED FEBRUARY 20, 2017 Over the past year, Zika Virus has become a signifi cant point of concern in our communities. As with any emergent illness or disease, it is important
More informationRelevant Communicable Diseases in HCT/Ps
Relevant Communicable Diseases in HCT/Ps Phyllis I. Warkentin, MD Professor of Pathology and Pediatrics University of Nebraska Medical Center FACT Chief Medical Officer Relevant Communicable Diseases in
More informationNorth Carolina Department of Health and Human Services Division of Public Health
North Carolina Department of Health and Human Services Division of Public Health Pat McCrory Governor February 8, 2016 (replaces version dated January 28, 2016) Richard O. Brajer Secretary Daniel Staley
More informationTesting - Pregnant Women
Testing - Pregnant Women 81% of women approved for testing in NJ were pregnant In 2017, nearly 95% of pregnant women tested were asymptomatic CDC Updated Testing Recommendations for Asymptomatic Pregnant
More informationAlberta Health Public Health Notifiable Disease Management Guidelines March 2017
Public Health Notifiable Disease Management Guidelines March 2017 Zika Virus Revision Dates Case Definition Reporting Requirements Epidemiology/Public Health Management March 2017 March 2017 March 2017
More informationThe pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado.
Health Alert Network Tri-County Health Department Serving Adams, Arapahoe and Douglas Counties Phone 303/220-9200 Fax 303/741-4173 www.tchd.org Follow us on Twitter @TCHDHealth and @TCHDEmergency John
More informationTown of Wolfeboro New Hampshire Health Notice Wolfeboro Public Health Officer Information Sheet Zika Virus
Aedes Zika Virus Information Sheet Town of Wolfeboro New Hampshire Health Notice Wolfeboro Public Health Officer Information Sheet Zika Virus The Zika Virus is a mosquito borne illness spread by the Aedes
More informationZika Virus What Every Woman Needs to Know
Zika Virus What Every Woman Needs to Know Carrie L. Byington, MD The Jean and Thomas McMullin Professor and Dean of Medicine Senior Vice President Health Science Center Vice Chancellor for Health Services
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: dos Santos T, Rodriguez A, Almiron M, et al. Zika virus and
More informationZika Update. Florida Department of Health Broward. Paula Thaqi, MD, MPH Director
Zika Update Florida Department of Health Broward 1 Paula Thaqi, MD, MPH Director Zika Virus Over 750,000 reported cases in the Americas Over 36,000 cases in U.S. territories Over 5,000 imported case sin
More informationZika Virus and Prevention in Mississippi
Mississippi State Department of Health Mississippi Morbidity Report Volume 32, Number 1 July 2016 Background: Zika Virus and Prevention in Mississippi Key Messages: Zika virus infection during pregnancy
More informationOutbreaks of Zika Virus: What Do We Know? Presented by Dr Jonathan Darbro Mosquito Control Lab, QIMR Berhgofer 15 September 2016
Outbreaks of Zika Virus: What Do We Know? Presented by Dr Jonathan Darbro Mosquito Control Lab, QIMR Berhgofer 15 September 2016 Overview History Distribution Modes of Transmission Symptoms Some Causal
More informationTO: Physicians, other Healthcare Providers, and Laboratories. Please distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians, other Healthcare Providers, and Laboratories Please distribute a copy of this information to each provider in your organization. Questions regarding this information may
More informationModule Three About Zika Virus: What is Known and Not Known
Module Three About Zika Virus: What is Known and Not Known HOUSEKEEPING For educational and quality improvement purposes, this TeleECHO Clinic will be recorded By participating in this clinic, you are
More informationZIKA VIRUS. Epic and aspects of management
ZIKA VIRUS Epic and aspects of management Classification - Belong to the family Flaviviridae which are mosquitoes borne viruses such as Dengue virus ( DEN V ), West Nile virus ( WN V ), Yellow fever Virus
More informationObjectives. Dengue, Chikungunya and Zika Virus Infection: Answers to Common Questions. Case 1. Dengue Introduction 10/15/2018
Dengue, Chikungunya and Zika Virus Infection: Answers to Common Questions Wayne Ghesquiere MD FRCPC Infectious Diseases Consultant Clinical Assistant Prof, UBC Victoria, BC Objectives Discuss common Arbovirus
More informationCenters for Disease Control and Prevention Zika Diagnosis: Challenges and Opportunities
Centers for Disease Control and Prevention Zika Diagnosis: Challenges and Opportunities Jorge L. Muñoz-Jordán, Ph.D. Chief, Surveillance and Research Laboratory Centers for Disease Control and Prevention
More information2017 SCAAP Summer Conference. Lilian Peake, MD, MPH
2017 SCAAP Summer Conference Lilian Peake, MD, MPH 1. Mosquito-borne Diseases 2. Challenges to Preventing and Controlling Mosquito-borne Diseases 3. Effects of Zika Virus on Child Health None Accelerating
More informationDisease Prevention, Detection & Response During Public Health Emergencies
Centers for Disease Control and Prevention Disease Prevention, Detection & Response During Public Health Emergencies Tom Frieden, MD, MPH Director, Centers for Disease Control and Prevention Global Disaster
More informationCDC An Overview for State and Territorial Leaders
Centers for Disease Control and Prevention CDC An Overview for State and Territorial Leaders Matthew Penn, JD, MLIS Director, Public Health Law Program Office for State, Tribal, Local and Territorial Support
More information3/29/2017. Zika in Northeast Ohio. Cuyahoga County Board of Health (CCBH)
Joe Lynch, RS, MPH Program Manager Environmental Public Health Cuyahoga County Board of Health Zika in Northeast Ohio Cuyahoga County Board of Health (CCBH) Take care of public health matters for over
More informationZika Virus. Lee Green Vector-Borne Epidemiologist Indiana State Department of Health. April 13, 2016
Zika Virus Lee Green Vector-Borne Epidemiologist Indiana State Department of Health April 13, 2016 What Is It? Flavivirus WNV Dengue St. Louis Encephalitis Yellow Fever Tick Borne Encephalitis Single stranded
More informationLocal Health Departments: Preparing for and Preventing Zika. March 23, 2016
Local Health Departments: Preparing for and Preventing Zika March 23, 2016 ZikaVirus Response Florida Department of Health (DOH) Jennifer Jackson, MPH and David Overfield 2016 2 Zika Virus Flavivirus:
More informationZika Virus: Epidemiology and Preparedness NH Emergency Preparedness Conference June 9, 2016
Zika Virus: Epidemiology and Preparedness NH Emergency Preparedness Conference June 9, 2016 Abigail Mathewson, DVM, MPH Surveillance Epidemiology Program Manager State Public Health Veterinarian Abigail.mathewson@dhhs.nh.gov
More informationZika Virus. Frequently Asked Questions: Zika Virus and Pregnancy Version
Zika Virus Frequently Asked Questions: Zika Virus and Pregnancy Version What is Zika? Zika is a viral infection that usually causes a mild illness that typically lasts between 2 and 7 days. 80% of people
More informationClinical Policy Title: Zika virus
Clinical Policy Title: Zika virus Clinical Policy Number: 17.01.04 Effective Date: October 1, 2016 Initial Review Date: May 18, 2016 Most Recent Review Date: May 18, 2016 Next Review Date: May 2017 Policy
More informationZika Virus: What Chicago Providers Need to Know
Zika Virus: What Chicago Providers Need to Know Stephanie R. Black, MD, MSc Medical Director, Communicable Disease Program Lisa Masinter, MD, MPH, MS Medical Director, Bureau of Maternal, Infant, Child
More informationUse of Treponemal Immunoassays for Screening and Diagnosis of Syphilis
Use of Treponemal Immunoassays for Screening and Diagnosis of Syphilis Guidance for Medical Providers and Laboratories in California These guidelines were developed by the California Department of Public
More information